Below are the most recent publications written about "Indazoles" by people in Profiles.
-
Castro E, Wang D, Walsh S, Craigie S, Haltner A, Nazari J, Niyazov A, Samjoo IA. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. Prostate Cancer Prostatic Dis. 2025 Sep; 28(3):817-827.
-
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, P?rez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, Gonz?lez-Mart?n A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
-
Gitto L, Wadsworth T, Isenschmid D, Krotulski AJ, Logan BK, Tarozzi I, Arunkumar P. MDMB-4en-PINACA-Related Deaths in Cook County Jail: Awareness and Preventive Measures. Am J Forensic Med Pathol. 2025 Mar 01; 46(1):87-91.
-
McKay RR, Morgans AK, Shore ND, Dunshee C, Devgan G, Agarwal N. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States. Cancer Treat Rev. 2024 May; 126:102726.
-
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024 Jun 10; 42(17):2061-2070.
-
Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 03; 46(3):228-238.
-
Norman C, Webling K, Kyslychenko O, Reid R, Krotulski AJ, Farrell R, Deventer MH, Liu H, Connolly MJ, Guillou C, Vinckier IMJ, Logan BK, NicDa?id N, McKenzie C, Stove CP, Gr?en H. Detection in seized samples, analytical characterization, and in vitro metabolism of the newly emerged 5-bromo-indazole-3-carboxamide synthetic cannabinoid receptor agonists. Drug Test Anal. 2024 Sep; 16(9):915-935.
-
Lacerda Q, Rochani A, Oeffinger B, Liu JB, Wessner CE, Tahmasebi A, Falatah H, Lee P, Leeper DB, Forsberg F, Curry J, Keith SW, O'Kane P, Kaushal G, Wheatley MA, Eisenbrey JR. Tumoral oxygenation and biodistribution of Lonidamine oxygen microbubbles following localized ultrasound-triggered delivery. Int J Pharm. 2022 Sep 25; 625:122072.
-
O'Cearbhaill RE, P?rez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, D?rum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, Gonz?lez-Mart?n A. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022 07; 166(1):36-43.
-
Carlson JJ, Italiano A, Brose MS, Federman N, Lassen U, Kummar S, Sullivan SD. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. Am J Manag Care. 2022 01; 28(2 Suppl):S26-S32.